Compare Biogen Inc (BIIB) vs NetApp Inc. (NTAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs NetApp Inc. — how do they compare? Biogen Inc trades at $206.69 (market cap $30.13B), while NetApp Inc. trades at $200.96 (market cap $38.95B). The key difference: NetApp Inc. is the larger of the two by market cap, and NetApp Inc. pays a 1.05% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | NTAP | |
|---|---|---|
Market Cap | $30.13B | $38.95B |
Sector | Health | Technology |
52-Week High | $216.63 | $198.72 |
52-Week Low | $128.93 | $94.11 |
Enterprise Value | $37.20B | $38.10B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
NetApp (NTAP) trades at $200.96, up 1.13% with strong technical momentum as it approaches resistance near $201. The stock shows robust fundamentals with consistent earnings beats (Q1 2026 EPS of $2.43 vs. $2.27 expected) and impressive profitability metrics including 70.74% gross margin and 106.73% ROE. Recent acquisitions of JetStream Software and DataPelago strengthen the company's AI infrastructure capabilities, positioning it for growth in the enterprise data storage market.
Outlook remains positive with Wall Street analysts maintaining a mixed but leaning bullish stance (36.62% Buy ratings). Key opportunities include AI-driven demand for data infrastructure, while risks involve elevated valuation multiples (P/E 31.26) and competitive pressures in the storage sector. The current price sits near analyst consensus target of $170.73, suggesting limited near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →
